These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 28562282

  • 1. Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease.
    Dallaire F, Fortier-Morissette Z, Blais S, Dhanrajani A, Basodan D, Renaud C, Mathew M, De Souza AM, Dionne A, Blanchard J, Saulnier H, Kaspy K, Rached-d'Astous S, Dahdah N, McCrindle BW, Human DG, Scuccimarri R.
    Pediatrics; 2017 Jun; 139(6):. PubMed ID: 28562282
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 03; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 4. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
    Dhanrajani A, Chan M, Pau S, Ellsworth J, Petty R, Guzman J.
    Arthritis Care Res (Hoboken); 2018 Oct 03; 70(10):1536-1540. PubMed ID: 29287309
    [Abstract] [Full Text] [Related]

  • 5. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B, Xu Z, Rong X, Chu M, Qiu H.
    Pediatr Rheumatol Online J; 2020 Jun 11; 18(1):48. PubMed ID: 32527316
    [Abstract] [Full Text] [Related]

  • 6. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
    Pediatr Neonatol; 2014 Oct 11; 55(5):387-92. PubMed ID: 24636168
    [Abstract] [Full Text] [Related]

  • 7. Medium- or Higher-Dose Acetylsalicylic Acid for Acute Kawasaki Disease and Patient Outcomes.
    Kim GB, Yu JJ, Yoon KL, Jeong SI, Song YH, Han JW, Hong YM, Joo CU.
    J Pediatr; 2017 May 11; 184():125-129.e1. PubMed ID: 28043685
    [Abstract] [Full Text] [Related]

  • 8. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 May 11; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 9. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K.
    Eur J Pediatr; 1994 Sep 11; 153(9):663-7. PubMed ID: 7957426
    [Abstract] [Full Text] [Related]

  • 10. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 11; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 11. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
    Saulsbury FT.
    Clin Pediatr (Phila); 2002 Oct 11; 41(8):597-601. PubMed ID: 12403377
    [Abstract] [Full Text] [Related]

  • 12. Acetylsalicylic acid for children with Kawasaki disease.
    Sakulchit T, Benseler SM, Goldman RD.
    Can Fam Physician; 2017 Aug 11; 63(8):607-609. PubMed ID: 28807954
    [Abstract] [Full Text] [Related]

  • 13. Initial intravenous immunoglobulin therapy without aspirin for acute Kawasaki disease: a retrospective cohort study with a Bayesian inference.
    Hayashi K, Miyakoshi C, Hoshino S, Kobayashi N, Nakajima R, Sagawa H, Hayashiya T, Suzuki A, Aota C, Nishijima S, Shimizu Y, Yamakawa M, Tsuda E.
    BMJ Paediatr Open; 2024 Jan 17; 8(1):. PubMed ID: 38233084
    [Abstract] [Full Text] [Related]

  • 14. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 15. Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan.
    Suzuki T, Michihata N, Hashimoto Y, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2024 Jan 17; 183(1):415-424. PubMed ID: 37917176
    [Abstract] [Full Text] [Related]

  • 16. Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High-Risk Patients With Kawasaki Disease.
    Ae R, Abrams JY, Maddox RA, Schonberger LB, Nakamura Y, Kuwabara M, Makino N, Matsubara Y, Kosami K, Sasahara T, Belay ED.
    J Am Heart Assoc; 2020 Sep 17; 9(17):e015308. PubMed ID: 32811256
    [Abstract] [Full Text] [Related]

  • 17. Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial.
    Wu Y, Hu L, Xie X, Li W, Wang Y, Zhang L, Huang P, Li F, Li J, Xia S, Yuan J, Li M, Wang Z, Zhang X.
    Am Heart J; 2024 Jul 17; 273():1-9. PubMed ID: 38508571
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
    Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP, Pediatric Heart Network Investigators.
    N Engl J Med; 2007 Feb 15; 356(7):663-75. PubMed ID: 17301297
    [Abstract] [Full Text] [Related]

  • 19. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, Iemura M, Ishii M, Kato H.
    Pediatr Int; 1999 Feb 15; 41(1):1-7. PubMed ID: 10200128
    [Abstract] [Full Text] [Related]

  • 20. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.
    Chiang MH, Liu HE, Wang JL.
    Arch Dis Child; 2021 Jul 15; 106(7):662-668. PubMed ID: 33172886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.